Jilin Jian Yisheng Pharmaceutical Co., Ltd. (SHE:002566)
China · Delayed Price · Currency is CNY 7.66
-0.01 (-0.13%)
Apr 22, 2026, 11:54 AM CST
SHE:002566 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 640.17 | 665.38 | 850.63 | 829.06 | 875.14 |
Other Revenue | - | 3.09 | 3.03 | 0.98 | 2.79 |
| 640.17 | 668.47 | 853.66 | 830.04 | 877.93 | |
Revenue Growth (YoY) | -4.23% | -21.69% | 2.85% | -5.46% | 4.19% |
Cost of Revenue | 166.5 | 174.13 | 224.8 | 215.44 | 221.22 |
Gross Profit | 473.67 | 494.34 | 628.87 | 614.6 | 656.71 |
Selling, General & Admin | 417.15 | 428.17 | 509.94 | 489.33 | 506.34 |
Research & Development | 15.14 | 16.22 | 18.68 | 18.78 | 20.89 |
Other Operating Expenses | 2.55 | 14 | -6.62 | 16.5 | 15.96 |
Operating Expenses | 434.84 | 458.4 | 522 | 525.88 | 542.74 |
Operating Income | 38.84 | 35.95 | 106.86 | 88.73 | 113.97 |
Interest Expense | - | -13.84 | -13.66 | -14.03 | -13.36 |
Interest & Investment Income | 13.35 | 11.69 | 16.31 | 11.14 | 9.27 |
Currency Exchange Gain (Loss) | - | -0.14 | -0.12 | -0 | - |
Other Non Operating Income (Expenses) | -16.26 | 0.23 | -0.57 | -1.92 | 0.13 |
EBT Excluding Unusual Items | 35.93 | 33.89 | 108.83 | 83.91 | 110.01 |
Gain (Loss) on Sale of Investments | -3.82 | 6.41 | 2.39 | -0.32 | 0.16 |
Gain (Loss) on Sale of Assets | 0.4 | 0.29 | 0.78 | - | - |
Asset Writedown | -2.44 | -0.27 | -0.24 | -0.27 | -0.28 |
Other Unusual Items | - | 19.22 | 0 | 17.9 | 13.48 |
Pretax Income | 30.06 | 59.55 | 111.76 | 101.23 | 123.37 |
Income Tax Expense | 1.13 | 8.89 | 15.65 | 12.91 | 18.67 |
Earnings From Continuing Operations | 28.93 | 50.66 | 96.11 | 88.32 | 104.7 |
Minority Interest in Earnings | 0.07 | 1.43 | -1.38 | -5.22 | -8.68 |
Net Income | 29 | 52.09 | 94.73 | 83.1 | 96.02 |
Net Income to Common | 29 | 52.09 | 94.73 | 83.1 | 96.02 |
Net Income Growth | -44.32% | -45.02% | 14.00% | -13.46% | 19.93% |
Shares Outstanding (Basic) | 331 | 331 | 331 | 331 | 331 |
Shares Outstanding (Diluted) | 331 | 331 | 331 | 331 | 331 |
Shares Change (YoY) | 0.04% | -0.03% | 0.02% | -0.02% | 0.01% |
EPS (Basic) | 0.09 | 0.16 | 0.29 | 0.25 | 0.29 |
EPS (Diluted) | 0.09 | 0.16 | 0.29 | 0.25 | 0.29 |
EPS Growth | -44.35% | -45.00% | 13.98% | -13.44% | 19.93% |
Free Cash Flow | 85.1 | 43 | 173.36 | 104.49 | 108.04 |
Free Cash Flow Per Share | 0.26 | 0.13 | 0.52 | 0.32 | 0.33 |
Dividend Per Share | - | 0.100 | 0.150 | 0.050 | 0.030 |
Dividend Growth | - | -33.33% | 200.00% | 66.67% | - |
Gross Margin | 73.99% | 73.95% | 73.67% | 74.05% | 74.80% |
Operating Margin | 6.07% | 5.38% | 12.52% | 10.69% | 12.98% |
Profit Margin | 4.53% | 7.79% | 11.10% | 10.01% | 10.94% |
Free Cash Flow Margin | 13.29% | 6.43% | 20.31% | 12.59% | 12.31% |
EBITDA | 77.34 | 78.56 | 152.08 | 128.82 | 154.25 |
EBITDA Margin | 12.08% | 11.75% | 17.82% | 15.52% | 17.57% |
D&A For EBITDA | 38.5 | 42.61 | 45.21 | 40.09 | 40.28 |
EBIT | 38.84 | 35.95 | 106.86 | 88.73 | 113.97 |
EBIT Margin | 6.07% | 5.38% | 12.52% | 10.69% | 12.98% |
Effective Tax Rate | 3.76% | 14.93% | 14.00% | 12.75% | 15.14% |
Revenue as Reported | - | 668.47 | 853.66 | 830.04 | 877.93 |
Advertising Expenses | - | 6.21 | 6.7 | 4.4 | 7.97 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.